CRBP Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595097 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.3%
TTM EPS YoY-10.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-131.5%
ROA-100.1%
ROIC (approx.)-160.1%
Asset turnover—
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-20.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $0 | $881,705 |
| R&D expense | $70.09M | $32.22M | $31.17M | $16.14M | $36.45M |
| SG&A expense | $15.21M | $16.50M | $13.91M | $18.70M | $20.43M |
| Operating income | -$85.31M | -$48.72M | -$45.08M | -$39.84M | -$55.99M |
| Interest expense | $0 | $1.87M | $3.86M | $3.10M | $2.71M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -$45.64M |
| EBITDA | -$85.08M | -$48.13M | -$44.44M | -$39.07M | -$54.99M |
| EPS (basic) | -5.90 | -3.68 | -10.31 | -10.15 | -11.15 |
| EPS (diluted) | -5.90 | -3.68 | -10.31 | -10.15 | -11.15 |
| Weighted avg. shares (diluted) | 13.32M | 10.92M | 4.33M | 4.17M | 4.09M |
| Banking | |||||
| Net interest income | — | — | -$2.92M | -$2.13M | -$1.83M |
| Balance sheet | |||||
| Cash & equivalents | $28.49M | $17.20M | $13.72M | $17.00M | $25.01M |
| Short-term investments | $134.78M | $131.86M | $7.18M | $42.19M | $72.64M |
| Current assets | $166.95M | $152.98M | $23.55M | $60.18M | $100.20M |
| PP&E, net | $159,000 | $385,000 | $973,000 | $1.61M | $2.39M |
| Total assets | $168.19M | $155.88M | $28.27M | $66.31M | $107.73M |
| Current liabilities | $20.69M | $11.82M | $31.89M | $12.64M | $17.01M |
| Short-term debt | — | — | $15.91M | $2.80M | $3.09M |
| Long-term debt | — | — | $0 | $15.98M | $15.64M |
| Total debt | — | — | $15.91M | $18.78M | $18.73M |
| Total liabilities | $20.69M | $13.45M | $35.18M | $33.32M | $38.62M |
| Shareholders' equity | $147.50M | $142.43M | -$6.91M | $32.99M | $69.11M |
| Net debt | — | — | $2.18M | $1.78M | -$6.28M |
| Shares outstanding | 17.61M | 12.18M | 4.42M | 4.17M | 4.17M |
| Cash flow statement | |||||
| Operating cash flow | -$64.49M | -$41.79M | -$36.10M | -$37.54M | -$48.18M |
| Capital expenditure | $7,000 | $0 | $0 | $13,449 | $54,172 |
| Free cash flow | -$64.50M | -$41.79M | -$36.10M | -$37.56M | -$48.24M |
| Investing cash flow | -$1.64M | -$121.31M | $35.64M | $30.07M | -$73.42M |
| Financing cash flow | $77.43M | $166.58M | -$2.82M | -$533,615 | $60.82M |
| Depreciation & amortization | $233,000 | $588,000 | $641,000 | $762,995 | $999,817 |
| Stock-based compensation | $6.29M | $6.14M | $3.47M | $5.72M | $9.48M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.